BiotechTube

AUTO CAR T cell therapy

Phase 2Recruiting
0 views this week 0 watching💤 Quiet🧪Featured in Gene & Cell Therapy Watch
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy

Conditions

Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma, DLBCL, ALL, Adult and Pediatric, T Cell Lymphoma

Trial Timeline

Aug 2, 2018 → Dec 1, 2043

NCT ID
NCT03628612

About AUTO CAR T cell therapy

AUTO CAR T cell therapy is a phase 2 stage product being developed by Autolus Therapeutics for Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03628612. Target conditions include Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma, DLBCL.

What happened to similar drugs?

18 of 20 similar drugs in Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy were approved

Approved (18) Terminated (1) Active (2)
✅ATG-FAstellas PharmaApproved
✅Clopidogrel + TicagrelorAstraZenecaApproved
✅OlaparibAstraZenecaApproved
✅BenralizumabAstraZenecaApproved
✅GefitinibAstraZenecaApproved
✅Imipenem + ImipenemMerckApproved
✅Cyclosporine - cyclosporine microemulsionNovartisApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03628612Phase 2Recruiting

Competing Products

20 competing products in Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy

See all competitors
ProductCompanyStageHype Score
R744 + R744Chugai PharmaceuticalPhase 3
40
R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placeboChugai PharmaceuticalPhase 3
40
R744 + Epoetin betaChugai PharmaceuticalPhase 3
40
R744 + R744Chugai PharmaceuticalPhase 3
40
R744 + R744Chugai PharmaceuticalPhase 3
40
R744Chugai PharmaceuticalPhase 3
40
PLX3397 + TemozolomideDaiichi SankyoPhase 1/2
32
FK949EAstellas PharmaPhase 1
29
roxadustatAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40
Roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
ASP8825Astellas PharmaPhase 1
29
ASP015KAstellas PharmaPhase 1
29
ASP7991Astellas PharmaPhase 1
29
Roxadustat + Epoetin AlfaAstellas PharmaPhase 3
40
ATG-FAstellas PharmaApproved
43
CelecoxibAstellas PharmaPre-clinical
26
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40
FK949EAstellas PharmaPhase 1
29